

# Special Issue

## Thrombosis and Coagulopathy

### Message from the Guest Editor

Cancer patients are at higher risk of developing thromboembolic events. Low-molecular-weight heparin remains the standard anticoagulant therapy in a cancer setting. However, direct oral anticoagulants have recently changed the therapeutic approach to the treatment of venous thromboembolism in cancer patients. This Special Issue will focus on the treatment of venous thromboembolism in patients affected by solid and hematologic malignancies.

---

### Guest Editor

Dr. Antonio Chistolini

Hematology Department of Translational and Precision Medicine,  
Sapienza University of Rome, Rome, Italy

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Diseases

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/59846](https://mdpi.com/si/59846)

*Diseases*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[diseases@mdpi.com](mailto:diseases@mdpi.com)

[mdpi.com/journal/  
diseases](https://mdpi.com/journal/diseases)





# Diseases

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
diseases](https://mdpi.com/journal/diseases)



## About the Journal

### Message from the Editorial Board

*Diseases* is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

*Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

---

### Editors-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of Medicine, Università Politecnica delle  
Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of  
Valencia, 46010 Valencia, Spain

---

### Author Benefits

#### High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

#### Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.